Stayble Therapeutics recently announced that the company's phase IIb study did not meet the primary endpoint. The drug candidate STA363 did not show a statistically significant reduction in pain compared to placebo after 6 months. The company now plans to continue evaluating top-line data from the study to create a better understanding of the results.
Read the full article at biostock.se:
https://www.biostock.se/en/2023/11/stayble-did-not-reach-the-primary-endpoint-in-phase-iib/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se